Medpace (MEDP) EVP Susan Burwig exercises 10,984 stock options into shares

Rhea-AI Filing Summary

Medpace Holdings, Inc. executive Susan E. Burwig exercised stock options to acquire 10,984 common shares on February 13, 2026. The options, with an exercise price of $107.93 per share, were fully vested as of February 28, 2020. Following the transaction, she directly owns 58,484 Medpace common shares. The exercised employee stock option derivative position is now fully exhausted, with zero derivative securities remaining.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		10,984	A	$107.93	58,484	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$107.93	02/13/2026		M			10,984	(1)	02/28/2026	Common Stock	10,984	$0	0	D

Explanation of Responses:

1. The option vested in full on February 28, 2020.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace (MEDP) report for Susan E. Burwig?

Medpace reported that executive Susan E. Burwig exercised employee stock options to acquire 10,984 common shares on February 13, 2026. This was an option exercise, not an open-market purchase or sale, and reflects conversion of a vested derivative security into common stock.

At what price were Susan E. Burwig’s Medpace (MEDP) options exercised?

The employee stock options were exercised at an exercise price of $107.93 per share. This price is specified as the conversion or exercise price of the derivative security that yielded 10,984 Medpace common shares in the reported February 13, 2026 transaction.

How many Medpace (MEDP) shares does Susan E. Burwig own after this Form 4?

After the reported transaction, Susan E. Burwig directly owns 58,484 Medpace common shares. This total reflects her holdings immediately following the February 13, 2026 option exercise that converted 10,984 options into common stock under her employee stock option award.

What happened to Susan E. Burwig’s Medpace (MEDP) employee stock options?

She exercised 10,984 employee stock options, fully converting them into common shares and leaving zero derivative securities from that grant. The filing notes the option vested in full on February 28, 2020, before being exercised on February 13, 2026.

What role does Susan E. Burwig hold at Medpace (MEDP)?

Susan E. Burwig is identified as an officer of Medpace Holdings, Inc., serving as Executive Vice President, Operations. Her role is disclosed in the Form 4, which reports her direct beneficial ownership and the stock option exercise transaction on February 13, 2026.